All TreatGx users now have access to the updated Epilepsy and Rheumatoid Arthritis treatment algorithms.
The Epilepsy update includes comprehensive treatment recommendations for specific types of epilepsy from the latest international guidelines, including the National Institute for Health and Care Excellence [1], Scottish Intercollegiate Guidelines Network [2], and American Academy of Neurology/American Epilepsy Society [3].
The newest version also features:
- A simplified approach to classification of epilepsy types: Focal/Partial or Generalized Epilepsy
- Updates to dosing for included medications based on newest monograph information and dose-adjusted for kidney function, liver function, drug-drug interactions, pharmacogenetics, and other patient-specific factors
- A new medication added for users in the US: zonisamide
- Useful prescribing information on off-label use and official indications per Health Canada and the FDA
The Rheumatoid Arthritis update includes comprehensive treatment recommendations using a simplified approach that allows clinicians to select from a large range of treatment strategies. The latest international guidelines were used to develop the algorithm, including the EULAR [4], American College of Rheumatology [5], National Institute for Health and Care Excellence [6], and Canadian Rheumatology Association guidelines [7].
The newest version also features:
- Inclusion of biological DMARD treatments, including biosimilars when available
- Automatic calculation of bodyweight-based doses
- Updates to dosing for included medications based on newest monograph information and dose-adjusted for kidney function, liver function, drug-drug interactions, pharmacogenetics, and other patient-specific factors
- National Institute for Health and Care Excellence, in Epilepsies: diagnosis and management. 2012, Updated 2020: London.
- Scottish Intercollegiate Guidelines Network (SIGN) Diagnosis and management of epilepsy in adults. 2015 updated 2018. SIGN publication no. 143.
- Kanner, A.M., et al., Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology, 2018. 91(2): p. 74-81.
- Rheumatism, T.E.L.A. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs: 2019 update 2020.
- Singh, J., et al., 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research, 2015.
- National Institute for Health and Care Excellence Drug treatment for rheumatoid arthritis. 2018.
- Bombardier, C., et al., Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol, 2012. 39(8): p. 1583-602.